1354000-30-8

Basic information

• Product Name: [(R)-1-(2-Hydroxy-ethyl)-pyrrolidin-3-yl]-carbaMic acid tert-butyl ester
• Synonyms: [(R)-1-(2-Hydroxy-ethyl)-pyrrolidin-3-yl]-carbaMic acid tert-butyl ester
• CAS NO: 1354000-30-8
• Molecular Formula: C11H22N2O3
• Molecular Weight: 230.30398
• Mol File: 1354000-30-8.mol
• Article Data: 3

Chemical Properties

• Appearance: /
• CAS DataBase Reference: [(R)-1-(2-Hydroxy-ethyl)-pyrrolidin-3-yl]-carbaMic acid tert-butyl ester(CAS DataBase Reference)
• NIST Chemistry Reference: [(R)-1-(2-Hydroxy-ethyl)-pyrrolidin-3-yl]-carbaMic acid tert-butyl ester(1354000-30-8)
• EPA Substance Registry System: [(R)-1-(2-Hydroxy-ethyl)-pyrrolidin-3-yl]-carbaMic acid tert-butyl ester(1354000-30-8)

Safety Data

• Hazardous Substances Data: 1354000-30-8(Hazardous Substances Data)

Upstream product

• 122536-77-0 3-N-tert-butoxycarbonyl-3-(R)-aminopyrrolidine 
• 540-51-2 2-bromoethanol 
• 122536-76-9 3(S)-(tert-butoxycarbonylamino)pyrrolidine 

Relevant articles and documents

COMPOUNDS AND METHODS FOR THE TARGETED DEGRADATION OF BROMODOMAIN-CONTAINING PROTEINS

The present invention relates to bifunctional compounds, which find utility as modulators of targeted ubiquitination, especially inhibitors of a variety of polypeptides and other proteins which are degraded and/or otherwise inhibited by bifunctional compounds according to the present invention. In particular, the present invention is directed to compounds, which contain on one end a VHL ligand which binds to the ubiquitin ligase and on the other end a moiety which binds a target protein such that the target protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of that protein. The present invention exhibits a broad range of pharmacological activities associated with compounds according to the present invention, consistent with the degradation/inhibition of targeted polypeptides.

SUBSTITUTED HETEROCYCLIC COMPOUNDS AS TROPOMYOSIN RECEPTOR KINASE A (TRKA) INHIBITORS

The present application relates to a series of substituted pyrazolo[1,5-a]pyridine compounds, their use as tropomyosin receptor kinase (Trk) family protein kinase inhibitors, method of making and pharmaceutical compositions comprising such compounds.